InFlectis BioScience, a pioneer in developing first-in-class therapies for neuromuscular diseases, announced that it has been awarded a $943,000 grant to support recruitment and to investigate biomarkers in its Phase 2 clinical trial in patients with bulbar-onset ALS (NCT05508074).
Nantes, France--(Newsfile Corp. - January 3, 2024) - InFlectis BioScience, a pioneer in developing first-in-class therapies for neuromuscular diseases, announced that it has been awarded a $943,000 grant to support recruitment and to investigate biomarkers in its Phase 2 clinical trial in patients with bulbar-onset ALS (NCT05508074). The trial is investigating IFB-088 (INN: icerguastat), a multifunctional drug that modulates the PPP1R15A/PP1c phosphatase complex and inhibits NR2B-containing NMDAR. The potential of IFB-088 lies in its ability to target three major ALS cellular pathophysiological mechanisms to manage disease progression: protein aggregation, oxidative stress, and glutamate excitotoxicity.
To view the full announcement, including downloadable images, bios, and more, click here.
Key Takeaways:
- InFlectis Bioscience has been awarded a $943K grant from the ALS Association to support the recruitment of 50 patients by the end of January 2024 for its Phase 2 clinical trial evaluating IFB-088.
- The grant also supports a multi-omics approach, conducted by the IRCCS “Carlo Besta” Neurological Institute in Milan, Italy to investigate pharmacodynamic biomarker candidates, which will be useful in a future pivotal clinical study.
- The Phase 2 clinical study results will be reported by the end of 2024.
Click image above to view full announcement.
About InFlectis BioScience
InFlectis is a France-based drug discovery company developing first-in-class therapies for neuromuscular diseases. We are in clinical development with an orally available small molecule that has the potential to extend lives or improve the quality-of-life for people suffering from ALS and CMT, a rare and progressive hereditary nerve condition.
IRCCS Foundation “Carlo Besta” Neurological Institute
The Foundation of the Carlo Besta Neurological Institute (FINCB) is a “Foundation of Participation” including as Members of the Board of Governors representatives of the Italian Ministry of Health, the Region of Lombardy and the Municipality of Milan. FINCB is recognized by the Italian Ministry of Health as a Scientific Institute for Research, Hospitalization and Health Care (IRCCS) of public body. It is a national and international centre of excellence for the treatment of neurological diseases, and also undertakes research aimed to improve the diagnosis and treatment of these diseases. Its major lines of activities in patients’ care and research encompass child neurology, epilepsy, neuro-oncology, neuropathic pain, and genetic, cerebrovascular, neuroimmunological, neuromuscular and neurodegenerative disorders. The fundamental aims of FINCB are to provide high quality, ethical and efficient care and treatment to its patients, making use of the results of its own research and that of others, always putting the interests of patient first.
About ALS
Amyotrophic lateral sclerosis (ALS) is a progressive neurodegenerative disease that affects nerve cells in the brain and spinal cord. Over the course of the disease, people lose the ability to move, to speak, and eventually, to breathe. On average, it takes about a year before a final ALS diagnosis is made. The disease is always fatal, usually within five years of diagnosis. There is no cure.
Contacts:
Philippe Gu’edat
philippeguedat@inflectisbioscience.com
Source: Inflectis
To view the source version of this press release, please visit https://www.newsfilecorp.com/release/193070
